



Published in final edited form as:

Trends Cell Biol. 2018 April ; 28(4): 287–301. doi:10.1016/j.tcb.2017.11.008.

Long Noncoding RNA in Cancer: Wiring Signaling Circuitry

Chunru Lin^{1,2,*} and Liuqing Yang^{1,2,3,*}

¹Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

²The Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

³Center for RNA Interference and Non-Coding RNAs, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Summary

Long non-coding RNAs (lncRNAs), which are encoded by a vast less explored region of the human genome may hold missing drivers of cancer and have gained attention recently as a potentially crucial layer of cancer cell regulation. lncRNAs are aberrantly expressed in a broad spectrum of cancers, and they play key roles in promoting and maintaining tumor initiation and progression, demonstrating their clinical potential as biomarkers and therapeutic targets. Recent discoveries have revealed that lncRNAs act as key signal transduction mediators in cancer signaling pathways by interacting with proteins, RNA and lipids. Here we review the mechanisms by which lncRNAs regulate cellular responses to extracellular signals and discuss their clinical potential as diagnostic indicators, stratification markers, and therapeutic targets of combinatorial treatments.

Keywords

Long non-coding RNAs; Cancer; Biomarker; Metastasis; Signaling Pathway; Ligand; Receptor; Signal Transducer; Kinase; Effector; Anti-sense Oligonucleotides; Locked nucleic acid; Nanoparticle-delivered siRNAs

LncRNAs as diagnostic and prognostic markers for human cancer

It is being recognized that certain single-nucleotide polymorphisms (SNPs) are associated with cancer risk. Large-scale data analysis from cancer genome-wide association studies (GWAS) indicate that the majority of SNPs associate with non-coding genes [9, 10]. The majority of recurrent somatic mutations, copy number alterations and cancer related SNPs

*To whom correspondence should be addressed: clin2@mdanderson.org and lyang7@mdanderson.org.

Conflicts of Interest

None.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

are related to non-coding RNAs [11–13] (recently reviewed [14]), and the presence of risk SNPs may modulate the expression of corresponding non-coding RNAs. Among those non-coding genes, long non-coding RNAs (lncRNAs) are emerging as a new class of indispensable players involved in the development and progression of cancer [3–5]. Indeed, SNPs of lncRNAs have been shown to be associated with risk for prostate cancer [15, 16], lung cancer [17], breast cancer [18–20], among other cancer types [21, 22]. Moreover, the dysregulation of a number of lncRNA targets has correlated with the stage and prognosis of several tumor types [21, 22] including prostate cancer [15, 16], lung cancer [17], and breast cancer [18–20] as well as being linked to resistance against chemotherapy and targeted therapy [26–29]. Correlation analyses indicate that numerous lncRNAs are upregulated in cancer cells that are resistant to DNA damage inducers [30–33], anti-hormone therapies [34–36], targeted therapies [37], and signaling pathway inhibitors [18] (Figure 1). Indeed the expression of HOTAIR activates estrogen receptor (ER) target transcription program and contributes to the resistance of tamoxifen [36]. Loss-of-function studies using small hairpin RNA-based knockdown and CRISPR/cas9-mediated genetic depletion indicate that lncRNAs facilitate cancer cell growth, apoptosis resistance, and cell mobility [30, 38, 39]. Gain-of-function studies suggest that increased expression of lncRNAs may enhance cell viability during drug treatment [32, 36, 40].

lncRNA derives from a number of sources including intergenic regions, the anti-sense strand of the protein coding sequence, intronic transcription, and alternative splicing (reviewed in [1, 2]). A considerable percentage of known lncRNAs either reside within the cytosol or shuttle between the nucleus and the cytoplasm [41]. Current studies indicate that these cytoplasmic lncRNAs play important functional roles in modulating messenger RNA translation and decay in a base-pairing dependent manner [42–44] or by competing with a protein or miRNA-mediated mRNA decoy [45]. In addition, cytoplasmic lncRNAs have been shown to regulate cytoplasmic protein trafficking from the cytosol to the nucleus for transcriptional activation [46]. Recent studies have also indicated that lncRNAs may associate with proteins, cellular lipids, and metabolic intermediates (Figure 2).

Although still largely unexplored, it has been suggested that lncRNAs are essential mediators of intracellular signaling pathways. Here we describe emerging insights into the role of lncRNAs in regulating signaling pathways in cancer. New insights into the regulatory roles of lncRNAs in cancer for governing novel mechanisms and pathways by which cancer cells acquire their invasiveness and metastatic properties serves as the basis of a new approach in the fight against cancer. This understanding of lncRNAs in cancer signaling should stimulate new directions for future research endeavors and therapeutic options that focus on lncRNAs as novel cancer prognostic markers and therapeutic targets.

lncRNA directs the outcome of cell signaling pathways

In addressing the functional role of lncRNAs, one of the possible explanations is to identify the binding proteins of a given lncRNA (Box 1). Accumulating research has demonstrated that key signaling mediators, such as receptors, protein kinases and transcription factors, directly associate with lncRNAs and that their enzymatic activities are regulated by those lncRNAs (Figure 2). For example, *Lnc-DC* associates with STAT3 to prevent SHP1-

dependent dephosphorylation of STAT3, which leads to dendritic cell differentiation [47]. *NKILA*, the lncRNA that associates with I κ B, inhibits IKK-mediated I κ B phosphorylation at Ser32 and Ser36, via direct association with the I κ B N-terminus. Consequently, NF-kappa B (NF-kB) signaling is negatively regulated by *NKILA* to suppress cancer metastasis [46]. The lncRNA *NBR2* (neighbor of BRCA1 gene 2) has been demonstrated to associate with AMPK upon energy stress and to promote the kinase activity of AMPK [48]. Cardiac and apoptosis-related lncRNA (*Carlr*) associates with p65 NF-kB in macrophages cells, and knockdown of *Carlr* impairs the expression of NF-kB target genes [49]. A PI3K p85 subunit-interacting lncRNA, *AK023948*, positively regulates the AKT pathway in breast cancer [50]. In addition, *LINK-A* directly associates with the non-receptor tyrosine kinase BRK and promotes the recruitment of BRK to the liganded receptor EGFR, leading to hyper-activation of the EGF/BRK/HIF signaling pathway [51]. Moreover, *MAYA*, via interaction with the scaffold protein LLGL2 and the methyltransferase NSUN6, forms an RNA-protein complex for methylation of MST1, a master regulator of the Hippo-YAP pathway [52].

Box 1

Biochemical Approaches to identify lncRNA-protein Interactions

lncRNA Pulldown Combined with Mass Spectrometry

This is an unbiased and open-ended lncRNA pulldown assay for better understanding of the lncRNA-associated protein partners. Typically, the pulldown assay uses a RNA probe labeled with a high-affinity biotin tag which allows the probe to be recovered. After incubation, the biotinylated RNA probe can bind with a protein/protein complex in a cell lysate and then the complex is purified using magnetic streptavidin beads. The proteins are then eluted from the RNA and detected by Western blot or mass spectrometry. This assay has the advantages of enrichment of low-abundance protein targets, isolation of intact protein complexes, and being compatible with immunoblotting and mass spectrometry analysis. This methodology will drive the advances of studying lncRNA functions and the related mechanisms [18, 35, 51, 52, 129]

Capture Hybridization Analysis of RNA Targets (CHART)

This method has been used to identify RNA-bound DNA, RNA or protein partners, mainly focusing on the lncRNA molecules within nucleus [130, 131]. Briefly, the formaldehyde-cross-linked chromatin extracts will be subjected to target RNA capture using biotinylated anti-sense oligonucleotides. The DNA-RNA hybrids will be digested by RNase H and enriched by streptavidin beads. The CHART-enriched proteins could be subjected to mass spectrometry to identify proteins that associate with target RNA molecules [132].

Chromatin isolation by RNA purification (ChIRP)

Similar to the Chromatin IP (ChIP) assay and CHART assay, the ChIRP method is based on the biotinylated oligonucleotides to immunoprecipitate endogenous lncRNAs from cell or tissues to identify the lncRNA-associated DNA or proteins [133]. The probe design requires pre-screen and validation for maximum hybridization efficiency. Elutes from the

ChIRP method using magnetic streptavidin beads could be subjected to mass spectrometry or immunoblotting for protein analysis [134].

RNA Antisense Purification with Mass Spectrometry (RAP-MS)

Similar to the CHART and ChIRP methods, RAP techniques applies anti-sense oligonucleotides as probe for RNA capture [135]. Distinct from the two previous methods, RAP method using 90mer oligonucleotides to create stable DNA-RNA hybrids; applies UV-crosslinking to capture transient RNA-protein interaction by introducing covalent bonds; purify RNA-protein complex by stringent denaturing condition to limit unspecific binding; and quantitative determine RNA-binding proteins using Stable isotope labeling with amino acids in cell culture (SILAC) [135]. The RAP-MS method has been used to identify RNA-associated proteins of nuclear lncRNA or mitochondria lncRNAs [80].

Crosslinking immunoprecipitation (CLIP)-coupled with high-throughput sequencing (HTS)

In brief, after UV cross-linking, RNA are labeled with ^{32}P - γ -ATP and partially digested. The RNA-protein complex is immunoprecipitated using an antibody. The bound RNAs are ligated with an RNA linker (20 nucleotides) and the RNA-protein complex is subjected to SDS-PAGE and autoradiography. Under the +++ RNase condition, the bound RNAs are overdigested, which exhibits a ~7kD molecular weight shift (roughly the molecular weight of the RNA linker). Under the + RNase condition, the ~15–20kD molecular weight shift corresponds to the 26–41 nucleotide RNA fragments (minus the RNA linker). Therefore, the RNase over-digestion (+++ RNase condition) is considered the negative control, and the ~15–20kD molecular shift band is excised for the subsequent steps. The CLIP assay will yield a mixture of RNA fragments of 25–55 nucleotides, plus 2–20 nucleotide RNA linkers, which will be subjected to sequencing. HITS-CLIP has been used to demonstrate the binding RNA motif of a given protein [136].

***In vitro* RNA pulldown followed by dot-blot assay**

The biotinylated RNA and recombinant proteins are incubated to promote binding. The bound RNA is subjected to partial RNase digestion (+ RNase condition), and the remaining bound RNA will be subjected to protease K digestion and RNA extraction. The RNA, in fragments, will be hybridized to a dot-blot. The dot-blot is a nylon membrane spotted with 54–60mer antisense DNA oligonucleotides tiling along the lncRNA targets. After stringent washing, the protein-bound RNA sequence is visualized by detection of Streptavidin-HRP signals. Depending on the different sequence motifs (regions) bound and protected by interested proteins, these RNA sequence motifs are hybridized to different positions on the dot-blot. Using this method, it has been demonstrated that two distinct positions, corresponding to nt. 235–288 and nt. 991–1044 of **BCAR4**, directly bind to SNIP1 and PNUITS respectively [35]. Similarly, two regions of **LINK-A**, nucleotides 481–540 and nucleotides 781–840, associate with the two domains of BRK at the SH3 domain and the C-terminal tail [51]. Another example is that

the nucleotides 241–300 and 841–900 of **MAYA** are responsible for LLGL2 and NSUN6 binding respectively [52].

Recent observations indicate that certain lncRNAs associate with a variety of phospholipids [18]. Genome wide identification of lncRNAs in cell lipid fraction indicated that about 1.6% lncRNAs may associate with lipid directly or indirectly. By an open-ended screening, a cohort of lncRNAs, including XLOC-002384, SNHG6, SNHG9, RP11-383G10.5, and LINKC00607 exhibited particularly strong and specific interaction with Lysophosphatidic acid (LPA), Lysobisphosphatidic acids (LBPA), Phosphatidic acid (PA), cardiolipin, and PE respectively, suggesting that lncRNAs may play important roles in regulating lipid metabolism, lipid signaling, mitochondrial function, cholesterol transportation, or even the formation of multivesicular bodies [53–56].

In summary, the proposed functional roles of lncRNAs in regulating signaling cascades and crosstalk between pathways can be classified into six categories (Figure 3): (i) the “Merge” category refers to when an lncRNA could conjoin the kinases of neighboring pathways, allowing the pathways to work in parallel to mediate a common cellular effect. Thus, the ligand of either receptor is able to activate the effector, accelerating the consequent cellular response; (ii) in the “Switch” group, lncRNA may couple one receptor to multiple kinases, creating a junction in the pathway. When the appropriate ligand binds to the receptor, the linked kinases are each able to activate their respective effectors in response to that one signal protein; (iii) In response to the cellular environment and specific ligand, a lncRNA could ‘reroute’ and form a bridge between a kinase and one of many possible effectors. In this scenario, one receptor and its associated kinase are able to achieve an array of cellular effects in accordance to the cellular context; (iv) lncRNAs may also be categorized by their ability to “yield.” In the situation of antagonistic pathways, a lncRNA is able to mediate interaction between two kinases so that only one pathway is activated at a given time. Therefore, activation of a pathway is blocked when the other is already activated; (v) lncRNAs can also be classified into a “shortcut” group. In the presence of the lncRNA, the conventional kinase cascade could be bypassed in favor of a shortcut that enables a more direct route to activating the downstream effector. Consequently, the lncRNA allows for more rapid induction of the desired cellular response; and (vi) lncRNAs may “detour.” In instances where the conventional pathway is disrupted or blocked, lncRNAs may facilitate the formation of an alternative pathway by way of recruiting substitute pathway components or mediators. In response to poisons or inhibitors, a cellular effect may still be achieved by the more circuitous route enabled by the lncRNA.

lncRNA-protein interactions: the building blocks of cancer signaling cascades

The interactions between lncRNAs and binding proteins act as one of the major mechanisms for lncRNA-mediated signaling pathways. In addition to typical RNA binding domains, atypical RNA binding domains are less recognized, but they play important roles in mediating lncRNA-protein interaction. Indeed, recent evidence has indicated that classical RNA-binding domains, non-classical RNA binding domains and domains with unknown

RNA-binding domains all play critical roles in mediating RNA-protein interactions in given signaling pathways (Figure 4).

Open-ended proteomic studies using oligo-dT capture to identify the interactome of mRNAs and potentially polyadenylated non-coding RNAs have indicated that classical RNA-binding domains, non-classical RNA binding domains and domains with unknown RNA-binding all exhibit RNA-binding possibility [57]. Proteins harbor non-canonical RNA-binding domains, such as the zinc finger, WD40 and SAM domains, which all have demonstrable RNA-binding [57]. Structural analyses have demonstrated that WD40 repeats may form an RNA-binding surface that can interact with snRNAs *via* base-stacking interactions, which is required for the ribonucleic particle biogenesis [58, 59]. In cancer signaling pathways, the WD40 domains of LLGL2 mediate LLGL2-*MAYA* interaction, which is required for the RNA-protein complex formation [52]. Another example of WD40 domain mediation of RNA-protein interaction is LRRK2, in which the WD40 domain of this protein serine/threonine kinase is required for the association between LRRK2 and *LINK-A* [51].

Domains with unknown RNA-binding properties, including the DUF and SH3 domains, have also been suggested to be involved in RNA binding [57]. The DUF domain of Dicer has been shown to interact with single-stranded or double-stranded RNA [60, 61]. Characterization of the DUF domain of SNIP1 has revealed that it is essential for interaction with the lncRNA *BCAR4* [35]. The SH3 domain of BRK contributes to the BRK-*LINK-A* interaction and the consequent hyperactivation of BRK [51]. Evidence has also been reported that the kinase domain of protein kinases may be involved in RNA-kinase interactions. Characterization of the *NBR2*-AMPK interaction indicated that deletion of the C-terminal half of AMPK abolished the RNA-protein interaction [48]. Global characterization of unknown RNA binding domains indicated that unstructured domains exhibited potential RNA-binding, suggesting the diversity of lncRNA-protein interactions [62].

Unlike proteins, which contain domain structures that can provide pilot information on the potential function, cellular location, and regulation involved in RNA-protein interaction, RNA motifs involved in RNA-protein interaction are more challenging to define. Using cross-linking based technologies (Box 1), the RNA motifs responsible for protein binding could be identified. It has been demonstrated that two distinct positions, corresponding to nt. 235–288 and nt. 991–1044 of *BCAR4*, directly bind to SNIP1 and PNUTS respectively [35]. Similarly, two regions of *LINK-A*, nucleotides 481–540 and nucleotides 781–840, associate with the two domains of BRK at the SH3 domain and the C-terminal tail [51]. Another example is that the nucleotides 241–300 and 841–900 of *MAYA* are responsible for LLGL2 and NSUN6 binding respectively [52]. The requisition of the identified RNA motifs can be validated by deletion mutants and CRISPR/cas9-mediated genomic editing [18]. Using CRISPR/cas9 technology, the specific RNA motif could be engineered without affecting the flanking sequence and unlikely to affect the intrinsic expression status of the lncRNAs, which provide advantages in studying the cellular consequence of lncRNAs. The secondary and 3-dimensional structures of RNAs are likely to play important roles in RNA-protein interaction (Figure 4). Within our limited knowledge, the nucleotides located in the loop region of the RNA motif are critical for RNA-protein binding, and the hairpin loop is one of

the more common structures found in RNA molecules [63]. Crystallographic dissection of RNA-protein interactions is urgently needed to pinpoint the underlying molecular mechanisms.

LncRNAs directly associate with phospholipids and other small molecules

The observations that RNA association with the cell membrane is involved in the formation of the *Escherichia coli* signal recognition particle [64] and regulation of *Saccharomyces cerevisiae* cell membrane permeability [65] support the notion that RNA-lipid interactions are important to life. The association of polynucleotides with charged lipid membranes, including phosphatidylcholines (PC), phosphatidylethanolamine (PE), phosphatidylinositol (PI), and phosphatidylserine (PS), have been observed in the cell nucleus [66] and RNA virus [67]. Biophysical studies have suggested that the phospholipid bilayer can absorb single-stranded DNA and RNA [68, 69]. Membranes composed of cationic or zwitterionic phospholipids with bivalent cations associate with RNA [68, 70]. It is intriguing that lncRNAs have been shown to interact with phospholipids with strong binding affinity, which are comparable to lipid-binding proteins [18, 71–73]. However, RNA-lipid interactions in their appropriate biological context need to be further demonstrated.

RNA nucleotides contain a negatively charged backbone and nitrogenous bases that possess a weak positive charge. The interaction between RNAs and phospholipids may be explained by the 3-dimensional structure of RNA. Structural analysis has shown that the loop structures of RNA molecules may be important for such binding [74]. It has been indicated that an 18 nucleotide stem-loop structure is required for *LINK-A*-PIP₃ interaction. Deletion of the loop region, or mutations of either 4' C to A or 6' C to A abolished RNA-PIP₃ interaction [18]. It is likely that the loop formed by the RNA molecules arranges the negatively charged backbone into a circle. It is possible that the cytosine bases at the 4' and 6' positions are arranged toward the center of the loop, allowing for potential hydrogen bonding with the three phospho-groups of PIP₃. In addition to this particular stem-loop structure, other parts of *LINK-A* may also contribute to the *LINK-A*-PIP₃ interaction. Ultimately, to understand the 3-dimensional interaction between *LINK-A* and PIP₃ will require structural analysis using crystallography or nuclear magnetic resonance (NMR).

In addition to macromolecules, RNAs have been demonstrated to associate with small molecules, including metal complexes, amino acids, and other organic or inorganic complexes [75]. Structural studies indicate that RNA molecules associates with arginine, which triggers a conformational change in the secondary structure of the RNA [76]. Hence, RNA molecules can likely serve as sensors for the regulation of metabolic pathways.

LncRNAs modulate enzyme activity

The functional roles of lncRNA-protein interactions are diverse. One of the surprising, yet frequent, observations is that once a protein binds with an lncRNA, the enzymatic activity of the binding protein may be modulated. For instance, the lncRNA *NBR2* has been indicated as an AMPK activator upon energy stress [48]. It has been demonstrated that lncRNAs can modulate the activity of various enzymes (e.g., kinases) in the following ways (Figure 5).

LncRNAs can modulate the activity of various enzymes (e.g., kinases) by acting as “Chaperones,” whereby lncRNA interacts with subunits of an enzyme and can induce a conformational change, altering its enzymatic activity. BRK is negatively regulated by its C-terminus, which harbors a phosphorylated tyrosine [77]. Protease digestion assay suggest a potential conformational change in BRK upon *LINK-A* binding on both the SH3 domain and C-terminus of BRK, which attenuates its self-inhibition, leading to enhanced enzymatic activity of BRK [51].

LncRNAs can modulate enzyme activity by acting as “Allosteric Regulators,” whereby lncRNA binds to the allosteric site of the enzyme, modifying the conformation of the active site. One example is that the PH domain of AKT serves as docking site to associate with PIP₃, which modulate the kinase activity of AKT [78]. The presence of *LINK-A* enhances the interaction between PH domain and PIP₃, leading to hyper-activation of AKT [18]. Another example is that long non-coding RNAs that are upregulated in breast cancer brain metastasis associates with the negative regulatory domain of JAK2, leading to alleviation of the inhibitory role of JH2 domain, and enzymatic activation [79].

LncRNAs may act as “Synergizers”, by which lncRNA conjoins multiple enzymes and/or regulators together, mediating cooperative action on its effectors or substrates. Recent studies indicate that the lncRNA *AK023948* associates with both DHX9 and p85 and that the presence of *AK023948* is required for the DHX9-p85 interaction, consequently resulting in enhanced PI3K activity and AKT phosphorylation [50]. Another example is that upon ligand binding, the signaling events trigger RNA-protein complex formation containing LLGL2-*MAYA*-NSUN6. LLGL2 recruits the substrate MST1 to the complex; NSUN6 acts as the methyltransferase; and *MAYA*, the lncRNA, serves as a scaffold that bridges the interaction between LLGL2 and NSUN6 upon extracellular stimulation, leading to MST1 methylation [52].

Alternatively, the lncRNA can also “Camouflage” or disguise the surface of target proteins, preventing the reorganization and post-translational modification of target proteins by upstream signaling events. *Lnc-DC* interacts with STAT3 in the cytoplasm, preventing SHP1-dependent dephosphorylation of STAT3 (Tyr705). These events facilitate the differentiation of dendritic cells [47]. *NKILA* is upregulated in breast cancer and associates with IκB, preventing IKK-dependent IκB phosphorylation at Ser32/36 [46]. Hence, it is clear that signaling pathways in cancer and other cellular activities are tightly regulated by lncRNAs.

The diverse roles of lncRNAs may also contribute to the relocalization of binding proteins as “Transporters”. Recent studies indicate that the lncRNA *SAMMSON* associates with p32, a mitochondria surface protein. The *SAMMSON*-p32 interaction facilitates relocalization of p32 to mitochondria, resulting in enhanced mitochondrial metabolism [80, 81]. The relocation of the lncRNA component of the RNA processing endoribonuclease (RMRP) from the nucleus to the mitochondria facilitates the accumulation of RMRP in the mitochondria, which is required for mitochondrial respiration [82]. Hence, lncRNA may communicate between nucleus and mitochondria for fine-tuning the cellular and mitochondrial activities [81].

Targeting lncRNAs in cancer therapy

From a clinical perspective, lncRNA serves as promising therapeutic targets. Multiple therapeutic strategies have been developed to target lncRNAs. Anti-sense oligonucleotide (ASO)-based strategies that downregulate the transcripts of lncRNAs via RNase H-dependent degradation are under active investigation (recently reviewed by Matsui and Corey [83]). Alternatively, liposome/nanoparticle delivered siRNAs have been developed to knockdown lncRNAs *in vivo* via Dicer- and Ago-dependent RNA silencing [84–86], which have been evaluated in xenograft models and have been found to inhibit tumorigenesis and long-distance metastasis [85, 87]. Small molecule inhibitors to block lncRNA-protein interactions or interfere with lncRNA-protein complexes formation are also on the rise [83]. Cancers frequently become resistant to administered chemotherapeutic agents. In these chemotherapy-resistant tumors, dysregulated lncRNAs can contribute significantly to the development of this resistance. Given the failure of certain pathway inhibitors during clinical trials, combinations of pathway-specific inhibitors integrated with a lncRNA-directed strategy may provide maximum efficacy in treating human cancer, which is under active investigation. Targeting lncRNAs using a variety of technologies, including anti-sense oligonucleotides-based strategies, siRNAs and small molecular inhibitors should be evaluated for their effects on cancer initiation, progression, metastasis and response to therapy.

Anti-sense oligonucleotide

Anti-sense oligonucleotide (ASO), including ASO gapmers [88], duplex RNA [89] and locked nucleic acids (LNAs) [90] binds to lncRNA transcripts via base-pairing. The RNA-DNA duplex triggers RNase-H-dependent cleavage [91]. The newer generation of ASOs incorporates chemical modification of the sugar backbone to improve binding affinity and *in vivo* stability [92, 93]. The Locked nucleic acids (LNAs) [90, 94, 95] and S-constrained ethyl (cEt) modifications [96] have been advanced to clinical trials [97–99]. LNAs are synthesized using modified RNA nucleotides, which contain an extra covalent bond between the 2'-O and 4'-C of the ribofuranose ring [100, 101]. The mixed LNA-DNA-LNA gapmers can base-pair with RNA targets, which can be used to silence RNA targets in cell line-based experiments and animal models. The incorporation of bridged nucleic acid (BNA) monomers can serve a similar purpose as LNAs [102]. The application of ASOs to knockdown lncRNAs *in vivo* has been tested in a variety of cancer models, with noteworthy inhibitory effects on tumor growth and progression [103, 104]. LNAs targeting *PVT1* have been shown to sensitize ovarian cancer cells to cisplatin, substantiating the effectiveness of combinatorial treatment [105]. Additionally, *lncARSR* promotes cancer cell resistance to Sunitinib, but cancer cell sensitivity to Sunitinib could be improved by targeting *lncARSR* using LNAs [106]. For lncRNAs that act as tumor suppressors, LNAs mimicking GAS5 binding sequence to the hormone receptors is sufficient to induce cancer cell apoptosis [107]. Clinical trial using LNAs targeting Bcl-2 oncoprotein [97], HIF1 α (NCT00466583), and AR [108] have shown promise and are under evaluation. Beyond its uses in cancer, LNAs have also been proposed to benefit patients with cardiovascular diseases [109], kidney diseases [110], neuronal disorders [111], and other human pathological conditions.

Nanoparticle-delivered siRNAs

Targeting lncRNAs using a siRNA-based strategy has been successfully applied in several preclinical models [112]. Recently, dioleoyl phosphatidylcholine (DOPC) based nanoliposomes have been developed for the delivery of nucleotide based-therapeutics (siRNA, microRNA, lncRNA and antisense oligos, etc.) for *in vivo* and clinical use [113–121]. Studies indicate that a single injection of DOPC-nanoliposomal siRNAs can inhibit the expression of target proteins for around 3–5 days in mouse tumors [119, 121]. DOPC nanoliposomes, with an average size of 50 nm, can be administered via a single intravenous or intraperitoneal injection to deliver select siRNAs and anti-miRs into tumor cells *in vivo*. This single administration produces a significant repression in the expression levels of the gene targets (e.g., Bcl2, eEF2K, FoxM1 and Kras or miRs155, miR34a, and JAK2) and in tumor size in mouse models and preclinical models of human cancer, including subcutaneous xenografts and orthotopic tumor models [79, 113–115, 117, 119, 121–123].

Small molecule inhibitors of lncRNAs

lncRNAs form complicated tertiary structures. Whether the secondary or 3-dimensional structure of lncRNAs molecules are conserved between species remain elusive [124]. One explanation is that a portion of the secondary or tertiary structures of lncRNA molecules, for example, key stem-loop structures for protein binding, are conserved; similar to the protein domain conservation that linker regions are variable. RNA molecules are potential targets for small molecule inhibitors. High-throughput screening has been employed to identify small molecule compounds that could potentially inhibit RNAs [125–127]. Efforts to establish platforms to aid the design and identification of small molecule inhibitors for oncogenic non-coding RNAs are under development [128], which will facilitate the large scale development of pharmaceutical agents that target lncRNAs.

Concluding Remarks

The interwoven signaling pathways present in many human cancer types complicate the development of targeted therapies or chemotherapeutic agents. lncRNAs play a pivotal role in mediating the crosstalk between the various cellular components, including proteins, RNAs, and lipids, that are involved in cancer cell signal transduction. Due to the prevalence of lncRNA involvement in cancer pathways, numerous studies have elucidated the importance of lncRNAs in various disease processes of cancer, including initiation, progression, invasion, and metastasis. Identification of the specific lncRNAs that function in various human cancer types has led to pioneering efforts to develop lncRNA-based clinical applications such as biomarkers for diagnosis, prognostic indicators, stratification markers, drug sensitizers, and therapeutic targets. The lncRNA profile of each human cancer type should be systematically investigated to improve clinical outcomes for cancer patients by engendering a personalized approach to medicine.

Future studies on the regulatory and biological roles of lncRNAs in cancer signaling will define the future of the field (see Outstanding Questions). Although a huge list of lncRNAs have been identified thus far, it has been a strenuous task to demonstrate the functional relevance of lncRNAs in cancer. To answer this problem, thorough examinations of lncRNA

candidates involved in cancer signaling pathway need to be conducted to reveal the physiological relevance of lncRNAs in cell apoptosis, survival, metastasis, and metabolism. Cellular and xenograft models have been the common means of studying the roles that lncRNAs play in cancer and are useful tools in cursory evaluations of their functions. However, conclusions that are more definitive will require representative *in vivo* models of cancer, such as genetic models that better recapitulate the tumor microenvironment. It will be crucial to determine if tissue-specific expression of lncRNAs, by genetic knock-in, can induce spontaneous tumor formation, which can then be blocked by targeting the lncRNAs.

Outstanding Questions

- Can lncRNAs serve as regulatory components of cancer signaling pathways?
- Do lncRNAs have *bona fide* biological functional roles in cancer?
- Can effective therapeutic strategies be developed by targeting either lncRNAs alone or in combination with chemotherapeutic and targeted therapy agents?

Acknowledgments

We apologize to colleagues whose work was not able to be included in this review due to space limitations. We thank Mr. D. Aten for assistance with figure presentation. We are grateful to Mr. Peter K. Park and Sergey Egranov for assistance with manuscript drafting. Research in the C. L. and L. Y. laboratories are funded by NIH R00 award (R00DK094981), R01 award (1R01 CA218025-01), and CPRIT (150094) to C.Lin., and the NIH R00 award (R00CA166527), R01 award (1R01 CA218036-01), CPRIT award (R1218), and DOD breakthrough (BC151465) grants to L.Y.

References

1. St Laurent G, et al. The Landscape of long noncoding RNA classification. *Trends Genet.* 2015; 31(5):239–51. [PubMed: 25869999]
2. Eddy SR. Non-coding RNA genes and the modern RNA world. *Nat Rev Genet.* 2001; 2(12):919–29. [PubMed: 11733745]
3. Prensner JR, Chinnaiyan AM. The emergence of lncRNAs in cancer biology. *Cancer Discov.* 2011; 1(5):391–407. [PubMed: 22096659]
4. Huarte M. The emerging role of lncRNAs in cancer. *Nat Med.* 2015; 21(11):1253–1261. [PubMed: 26540387]
5. Fatica A, Bozzoni I. Long non-coding RNAs: new players in cell differentiation and development. *Nat Rev Genet.* 2014; 15(1):7–21. [PubMed: 24296535]
6. Ye N, et al. Functional roles of long non-coding RNA in human breast cancer. *Asian Pac J Cancer Prev.* 2014; 15(15):5993–7. [PubMed: 25124562]
7. Meng J, et al. A four-long non-coding RNA signature in predicting breast cancer survival. *J Exp Clin Cancer Res.* 2014; 33:84. [PubMed: 25288503]
8. Huarte M, Rinn JL. Large non-coding RNAs: missing links in cancer? *Hum Mol Genet.* 2010; 19(R2):R152–61. [PubMed: 20729297]
9. Harrow J, et al. GENCODE: the reference human genome annotation for The ENCODE Project. *Genome Res.* 2012; 22(9):1760–74. [PubMed: 22955987]
10. Chen G, et al. Genome-wide analysis of human SNPs at long intergenic noncoding RNAs. *Hum Mutat.* 2013; 34(2):338–44. [PubMed: 23065742]
11. Melton C, et al. Recurrent somatic mutations in regulatory regions of human cancer genomes. *Nat Genet.* 2015; 47(7):710–6. [PubMed: 26053494]

12. Beroukhi R, et al. The landscape of somatic copy-number alteration across human cancers. *Nature*. 2010; 463(7283):899–905. [PubMed: 20164920]
13. Cheetham SW, et al. Long noncoding RNAs and the genetics of cancer. *Br J Cancer*. 2013; 108(12):2419–25. [PubMed: 23660942]
14. Khurana E, et al. Role of non-coding sequence variants in cancer. *Nat Rev Genet*. 2016; 17(2):93–108. [PubMed: 26781813]
15. Guo H, et al. Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. *Nat Genet*. 2016; 48(10):1142–50. [PubMed: 27526323]
16. Jin G, et al. Human polymorphisms at long non-coding RNAs (lncRNAs) and association with prostate cancer risk. *Carcinogenesis*. 2011; 32(11):1655–9. [PubMed: 21856995]
17. Yuan H, et al. A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. *Sci Rep*. 2016; 6:34234. [PubMed: 27713484]
18. Lin A, et al. The LINK-A lncRNA interacts with PtdIns(3,4,5)P3 to hyperactivate AKT and confer resistance to AKT inhibitors. *Nat Cell Biol*. 2017; 19(3):238–251. [PubMed: 28218907]
19. Xu T, et al. Association between SNPs in Long Non-coding RNAs and the Risk of Female Breast Cancer in a Chinese Population. *J Cancer*. 2017; 8(7):1162–1169. [PubMed: 28607590]
20. Xia Z, et al. Genetic Polymorphisms in Long Noncoding RNA H19 Are Associated With Susceptibility to Breast Cancer in Chinese Population. *Medicine (Baltimore)*. 2016; 95(7):e2771. [PubMed: 26886624]
21. Zhao X, et al. The rs6983267 SNP and long non-coding RNA CARLo-5 are associated with endometrial carcinoma. *Environ Mol Mutagen*. 2016; 57(7):508–15. [PubMed: 27432114]
22. Jendrzewski J, et al. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. *Proc Natl Acad Sci U S A*. 2012; 109(22):8646–51. [PubMed: 22586128]
23. Wu Q, et al. Polymorphisms in Long Noncoding RNA H19 Contribute to the Protective Effects of Coal Workers' Pneumoconiosis in a Chinese Population. *Int J Environ Res Public Health*. 2016; 13(9)
24. Millis MP, et al. Variants in the plasmacytoma variant translocation gene (PVT1) are associated with end-stage renal disease attributed to type 1 diabetes. *Diabetes*. 2007; 56(12):3027–32. [PubMed: 17881614]
25. Ingle JN, et al. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. *Cancer Res*. 2016; 76(23):7012–7023. [PubMed: 27758888]
26. Majidinia M, Yousefi B. Long non-coding RNAs in cancer drug resistance development. *DNA Repair (Amst)*. 2016; 45:25–33. [PubMed: 27427176]
27. Pan JJ, et al. Long Non-coding RNAs and Drug Resistance. *Asian Pac J Cancer Prev*. 2015; 16(18):8067–73. [PubMed: 26745040]
28. Askarian-Amiri ME, et al. The Regulatory Role of Long Noncoding RNAs in Cancer Drug Resistance. *Methods Mol Biol*. 2016; 1395:207–27. [PubMed: 26910076]
29. Chen QN, et al. Long non-coding RNAs in anti-cancer drug resistance. *Oncotarget*. 2017; 8(1):1925–1936. [PubMed: 27713133]
30. Zhang CL, et al. A long non-coding RNA contributes to doxorubicin resistance of osteosarcoma. *Tumour Biol*. 2016; 37(2):2737–48. [PubMed: 26408180]
31. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. *Oncogene*. 2007; 26(33):4877–81. [PubMed: 17297456]
32. Tsang WP, et al. Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. *RNA*. 2007; 13(6):890–8. [PubMed: 17416635]
33. Hou Z, et al. Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients. *PLoS One*. 2014; 9(9):e108133. [PubMed: 25250788]
34. Meijer D, et al. Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells. *Mol Cancer Res*. 2006; 4(6):379–86. [PubMed: 16778085]

35. Xing Z, et al. lncRNA Directs Cooperative Epigenetic Regulation Downstream of Chemokine Signals. *Cell*. 2014; 159(5):1110–25. [PubMed: 25416949]
36. Xue X, et al. lncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. *Oncogene*. 2016; 35(21):2746–55. [PubMed: 26364613]
37. Silveira RA, et al. Protein-coding genes and long noncoding RNAs are differentially expressed in dasatinib-treated chronic myeloid leukemia patients with resistance to imatinib. *Hematology*. 2014; 19(1):31–41. [PubMed: 23676950]
38. Hung T, et al. Extensive and coordinated transcription of noncoding RNAs within cell-cycle promoters. *Nat Genet*. 2011; 43(7):621–9. [PubMed: 21642992]
39. Wang Y, et al. Long noncoding RNA MRUL promotes ABCB1 expression in multidrug-resistant gastric cancer cell sublines. *Mol Cell Biol*. 2014; 34(17):3182–93. [PubMed: 24958102]
40. Fan Y, et al. Long non-coding RNA UCA1 increases chemoresistance of bladder cancer cells by regulating Wnt signaling. *FEBS J*. 2014; 281(7):1750–8. [PubMed: 24495014]
41. Rashid F, et al. Long Non-coding RNAs in the Cytoplasm. *Genomics Proteomics Bioinformatics*. 2016; 14(2):73–80. [PubMed: 27163185]
42. Kim YK, et al. Staufeni regulates diverse classes of mammalian transcripts. *EMBO J*. 2007; 26(11):2670–81. [PubMed: 17510634]
43. Gong C, Maquat LE. lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. *Nature*. 2011; 470(7333):284–8. [PubMed: 21307942]
44. Beltran M, et al. A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition. *Genes Dev*. 2008; 22(6):756–69. [PubMed: 18347095]
45. Cesana M, et al. A long noncoding RNA controls muscle differentiation by functioning as a competing endogenous RNA. *Cell*. 2011; 147(2):358–69. [PubMed: 22000014]
46. Liu B, et al. A cytoplasmic NF-kappaB interacting long noncoding RNA blocks IkappaB phosphorylation and suppresses breast cancer metastasis. *Cancer Cell*. 2015; 27(3):370–81. [PubMed: 25759022]
47. Wang P, et al. The STAT3-binding long noncoding RNA lnc-DC controls human dendritic cell differentiation. *Science*. 2014; 344(6181):310–3. [PubMed: 24744378]
48. Liu X, et al. lncRNA NBR2 engages a metabolic checkpoint by regulating AMPK under energy stress. *Nat Cell Biol*. 2016; 18(4):431–42. [PubMed: 26999735]
49. Castellanos-Rubio A, et al. Cytoplasmic Form of Carlr lncRNA Facilitates Inflammatory Gene Expression upon NF-kappaB Activation. *J Immunol*. 2017; 199(2):581–588. [PubMed: 28626066]
50. Koirala P, et al. lncRNA AK023948 is a positive regulator of AKT. *Nat Commun*. 2017; 8:14422. [PubMed: 28176758]
51. Lin A, et al. The LINK-A lncRNA activates normoxic HIF1alpha signalling in triple-negative breast cancer. *Nat Cell Biol*. 2016; 18(2):213–24. [PubMed: 26751287]
52. Li C, et al. A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis. *Nat Cell Biol*. 2017; 19(2):106–119. [PubMed: 28114269]
53. Lin ME, et al. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. *Prostaglandins Other Lipid Mediat*. 2010; 91(3–4):130–8. [PubMed: 20331961]
54. Zechner R, et al. FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling. *Cell Metab*. 2012; 15(3):279–91. [PubMed: 22405066]
55. Paradies G, et al. Functional role of cardiolipin in mitochondrial bioenergetics. *Biochim Biophys Acta*. 2014; 1837(4):408–17. [PubMed: 24183692]
56. Patel D, Witt SN. Ethanolamine and Phosphatidylethanolamine: Partners in Health and Disease. *Oxid Med Cell Longev*. 2017; 2017:4829180. [PubMed: 28785375]
57. Castello A, et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. *Cell*. 2012; 149(6):1393–406. [PubMed: 22658674]
58. Jin W, et al. Structural basis for snRNA recognition by the double-WD40 repeat domain of Gemin5. *Genes Dev*. 2016; 30(21):2391–2403. [PubMed: 27881601]
59. Bertram K, et al. Cryo-EM structure of a human spliceosome activated for step 2 of splicing. *Nature*. 2017; 542(7641):318–323. [PubMed: 28076346]

60. Dlakic M. DUF283 domain of Dicer proteins has a double-stranded RNA-binding fold. *Bioinformatics*. 2006; 22(22):2711–4. [PubMed: 16954143]
61. Kurzynska-Kokorniak A, et al. Revealing a new activity of the human Dicer DUF283 domain in vitro. *Sci Rep*. 2016; 6:23989. [PubMed: 27045313]
62. Castello A, et al. Comprehensive Identification of RNA-Binding Domains in Human Cells. *Mol Cell*. 2016; 63(4):696–710. [PubMed: 27453046]
63. Svoboda P, Di Cara A. Hairpin RNA: a secondary structure of primary importance. *Cell Mol Life Sci*. 2006; 63(7–8):901–8. [PubMed: 16568238]
64. Batey RT, et al. Crystal structure of the ribonucleoprotein core of the signal recognition particle. *Science*. 2000; 287(5456):1232–9. [PubMed: 10678824]
65. MacIntosh GC, et al. Characterization of Rny1, the *Saccharomyces cerevisiae* member of the T2 RNase family of RNases: unexpected functions for ancient enzymes? *Proc Natl Acad Sci U S A*. 2001; 98(3):1018–23. [PubMed: 11158587]
66. Lu D, Rhodes DG. Binding of phosphorothioate oligonucleotides to zwitterionic liposomes. *Biochim Biophys Acta*. 2002; 1563(1–2):45–52. [PubMed: 12007624]
67. Tuma R, et al. Structure, Interactions and Dynamics of PRD1 Virus II. Organization of the Viral Membrane and DNA. *Journal of Molecular Biology*. 1996; 257(1):102–115. [PubMed: 8632449]
68. Kõiv A, et al. Differential scanning calorimetry study on the binding of nucleic acids to dimyristoylphosphatidylcholine-sphingosine liposomes. *Chemistry and Physics of Lipids*. 1994; 70(1):1–10. [PubMed: 7516824]
69. Michanek A, et al. RNA and DNA interactions with zwitterionic and charged lipid membranes—A DSC and QCM-D study. *Biochimica et Biophysica Acta (BBA) - Biomembranes*. 2010; 1798(4): 829–838. [PubMed: 20036213]
70. Khvorova A, et al. RNAs that bind and change the permeability of phospholipid membranes. *Proc Natl Acad Sci U S A*. 1999; 96(19):10649–54. [PubMed: 10485880]
71. Frech M, et al. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. *J Biol Chem*. 1997; 272(13):8474–81. [PubMed: 9079675]
72. Ching TT, et al. Specific binding of the C-terminal Src homology 2 domain of the p85alpha subunit of phosphoinositide 3-kinase to phosphatidylinositol 3,4,5-trisphosphate. Localization and engineering of the phosphoinositide-binding motif. *J Biol Chem*. 2001; 276(47):43932–8. [PubMed: 11555646]
73. Yates LA, et al. Structural and functional characterization of the kindlin-1 pleckstrin homology domain. *J Biol Chem*. 2012; 287(52):43246–61. [PubMed: 23132860]
74. Childs-Disney JL, Disney MD. Approaches to Validate and Manipulate RNA Targets with Small Molecules in Cells. *Annu Rev Pharmacol Toxicol*. 2016; 56:123–40. [PubMed: 26514201]
75. Chow CS, Bogdan FM. A Structural Basis for RNAminus signLigand Interactions. *Chem Rev*. 1997; 97(5):1489–1514. [PubMed: 11851457]
76. Puglisi JD, et al. Conformation of the TAR RNA-arginine complex by NMR spectroscopy. *Science*. 1992; 257(5066):76–80. [PubMed: 1621097]
77. Qiu H, Miller WT. Regulation of the nonreceptor tyrosine kinase Brk by autophosphorylation and by autoinhibition. *J Biol Chem*. 2002; 277(37):34634–41. [PubMed: 12121988]
78. Bellacosa A, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. *Oncogene*. 1998; 17(3):313–25. [PubMed: 9690513]
79. Wang S, et al. JAK2-binding long noncoding RNA promotes breast cancer brain metastasis. *J Clin Invest*. 2017
80. Leucci E, et al. Melanoma addiction to the long non-coding RNA SAMMSON. *Nature*. 2016; 531(7595):518–22. [PubMed: 27008969]
81. Vendramin R, et al. Non-coding RNAs: the dark side of nuclear-mitochondrial communication. *EMBO J*. 2017; 36(9):1123–1133. [PubMed: 28314780]
82. Noh JH, et al. HuR and GRSF1 modulate the nuclear export and mitochondrial localization of the lncRNA RMRP. *Genes Dev*. 2016; 30(10):1224–39. [PubMed: 27198227]

83. Matsui M, Corey DR. Non-coding RNAs as drug targets. *Nat Rev Drug Discov.* 2017; 16(3):167–179. [PubMed: 27444227]
84. Buyens K, et al. Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design. *J Control Release.* 2012; 158(3):362–70. [PubMed: 22023849]
85. Lee JM, et al. Recent developments in nanoparticle-based siRNA delivery for cancer therapy. *Biomed Res Int.* 2013; 2013:782041. [PubMed: 23844368]
86. Carthew RW, Sontheimer EJ. Origins and Mechanisms of miRNAs and siRNAs. *Cell.* 2009; 136(4):642–55. [PubMed: 19239886]
87. Young SW, et al. Nanoparticle-siRNA: A potential cancer therapy? *Crit Rev Oncol Hematol.* 2016; 98:159–69. [PubMed: 26597018]
88. Kole R, et al. RNA therapeutics: beyond RNA interference and antisense oligonucleotides. *Nat Rev Drug Discov.* 2012; 11(2):125–40. [PubMed: 22262036]
89. Williams T, Fried M. A mouse locus at which transcription from both DNA strands produces mRNAs complementary at their 3' ends. *Nature.* 1986; 322(6076):275–9. [PubMed: 2874494]
90. Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. *Biochemistry.* 2004; 43(42):13233–41. [PubMed: 15491130]
91. Chan JH, et al. Antisense oligonucleotides: from design to therapeutic application. *Clin Exp Pharmacol Physiol.* 2006; 33(5–6):533–40. [PubMed: 16700890]
92. Geary RS, et al. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. *Adv Drug Deliv Rev.* 2015; 87:46–51. [PubMed: 25666165]
93. Moreno PM, Pego AP. Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic. *Front Chem.* 2014; 2:87. [PubMed: 25353019]
94. Sarma K, et al. Locked nucleic acids (LNAs) reveal sequence requirements and kinetics of Xist RNA localization to the X chromosome. *Proc Natl Acad Sci U S A.* 2010; 107(51):22196–201. [PubMed: 21135235]
95. You Y, et al. Design of LNA probes that improve mismatch discrimination. *Nucleic Acids Res.* 2006; 34(8):e60. [PubMed: 16670427]
96. Seth PP, et al. Design, synthesis and evaluation of constrained methoxyethyl (cMOE) and constrained ethyl (cEt) nucleoside analogs. *Nucleic Acids Symp Ser (Oxf).* 2008; (52):553–4.
97. Durig J, et al. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. *Leukemia.* 2011; 25(4):638–47. [PubMed: 21358717]
98. Hong D, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. *Sci Transl Med.* 2015; 7(314):314ra185.
99. Pandey SK, et al. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. *J Pharmacol Exp Ther.* 2015; 355(2):329–40. [PubMed: 26330536]
100. Tereshko V, et al. Crystal structures of the catalytic domain of human protein kinase associated with apoptosis and tumor suppression. *Nat Struct Biol.* 2001; 8(10):899–907. [PubMed: 11573098]
101. Kumar R, et al. The first analogues of LNA (locked nucleic acids): phosphorothioate-LNA and 2'-thio-LNA. *Bioorg Med Chem Lett.* 1998; 8(16):2219–22. [PubMed: 9873516]
102. Sekiguchi M, et al. Synthesis and properties of a novel bridged nucleic acid analogue, 5'-amino-3',5'-BNA. *Nucleosides Nucleotides Nucleic Acids.* 2005; 24(5–7):1097–100. [PubMed: 16248099]
103. Gutschner T, et al. The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. *Cancer Res.* 2013; 73(3):1180–9. [PubMed: 23243023]
104. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. *Oncogene.* 2003; 22(56):9087–96. [PubMed: 14663487]
105. Iden M, et al. The lncRNA PVT1 Contributes to the Cervical Cancer Phenotype and Associates with Poor Patient Prognosis. *PLoS One.* 2016; 11(5):e0156274. [PubMed: 27232880]

106. Qu L, et al. Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA. *Cancer Cell*. 2016; 29(5):653–68. [PubMed: 27117758]
107. Pickard MR, Williams GT. The hormone response element mimic sequence of GAS5 lncRNA is sufficient to induce apoptosis in breast cancer cells. *Oncotarget*. 2016; 7(9):10104–16. [PubMed: 26862727]
108. Bianchini D, et al. First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. *Br J Cancer*. 2013; 109(10):2579–86. [PubMed: 24169353]
109. Ottaviani L, da Costa Martins PA. Non-coding RNAs in cardiac hypertrophy. *J Physiol*. 2017; 595(12):4037–4050. [PubMed: 28233323]
110. Yang C, et al. Fighting against kidney diseases with small interfering RNA: opportunities and challenges. *J Transl Med*. 2015; 13:39. [PubMed: 25637948]
111. Khorkova O, Wahlestedt C. Oligonucleotide therapies for disorders of the nervous system. *Nat Biotechnol*. 2017; 35(3):249–263. [PubMed: 28244991]
112. Rupaimoole R, et al. Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. *Cell Rep*. 2015; 13(11):2395–402. [PubMed: 26686630]
113. Ozpolat B, et al. Liposomal siRNA nanocarriers for cancer therapy. *Adv Drug Deliv Rev*. 2014; 66:110–6. [PubMed: 24384374]
114. Tekedereli I, et al. Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (–) and ER (+) Breast Cancer. *Mol Ther Nucleic Acids*. 2013; 2:e121. [PubMed: 24022053]
115. Nick AM, et al. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. *J Natl Cancer Inst*. 2011; 103(21):1596–612. [PubMed: 21957230]
116. Naina HV, Harris S. Paraneoplastic thrombocytosis in ovarian cancer. *N Engl J Med*. 2012; 366(19):1840. author reply 1840. [PubMed: 22571210]
117. Nishimura M, et al. Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. *Cancer Discov*. 2013; 3(11):1302–15. [PubMed: 24002999]
118. Tekedereli I, et al. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. *PLoS One*. 2012; 7(7):e41171. [PubMed: 22911754]
119. Aslan B, et al. The ZNF304-integrin axis protects against anoikis in cancer. *Nat Commun*. 2015; 6:7351. [PubMed: 26081979]
120. Pradeep S, et al. Erythropoietin Stimulates Tumor Growth via EphB4. *Cancer Cell*. 2015; 28(5):610–22. [PubMed: 26481148]
121. Akar U, et al. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. *Mol Cancer Ther*. 2010; 9(5):1180–7. [PubMed: 20423989]
122. Kretz M, et al. Suppression of progenitor differentiation requires the long noncoding RNA ANCR. *Genes Dev*. 2012; 26(4):338–43. [PubMed: 22302877]
123. Ozpolat B, et al. Nanomedicine based approaches for the delivery of siRNA in cancer. *J Intern Med*. 2010; 267(1):44–53. [PubMed: 20059643]
124. Rivas E, et al. A statistical test for conserved RNA structure shows lack of evidence for structure in lncRNAs. *Nat Methods*. 2017; 14(1):45–48. [PubMed: 27819659]
125. Howe JA, et al. Selective small-molecule inhibition of an RNA structural element. *Nature*. 2015; 526(7575):672–7. [PubMed: 26416753]
126. Velagapudi SP, et al. Design of a small molecule against an oncogenic noncoding RNA. *Proc Natl Acad Sci U S A*. 2016; 113(21):5898–903. [PubMed: 27170187]
127. Connelly CM, et al. The Emerging Role of RNA as a Therapeutic Target for Small Molecules. *Cell Chem Biol*. 2016; 23(9):1077–90. [PubMed: 27593111]
128. Velagapudi SP, et al. Defining RNA-Small Molecule Affinity Landscapes Enables Design of a Small Molecule Inhibitor of an Oncogenic Noncoding RNA. *ACS Cent Sci*. 2017; 3(3):205–216. [PubMed: 28386598]

129. Jain AK, et al. LncPRESS1 Is a p53-Regulated LncRNA that Safeguards Pluripotency by Disrupting SIRT6-Mediated De-acetylation of Histone H3K56. *Mol Cell*. 2016; 64(5):967–981. [PubMed: 27912097]
130. Simon MD. Capture hybridization analysis of RNA targets (CHART). *Curr Protoc Mol Biol*. 2013; Chapter 21(Unit 21):25.
131. Simon MD, et al. The genomic binding sites of a noncoding RNA. *Proc Natl Acad Sci U S A*. 2011; 108(51):20497–502. [PubMed: 22143764]
132. Yang Y, et al. Unveiling the hidden function of long non-coding RNA by identifying its major partner-protein. *Cell Biosci*. 2015; 5:59. [PubMed: 26500759]
133. Chu C, et al. Chromatin isolation by RNA purification (ChIRP). *J Vis Exp*. 2012; (61)
134. Chu C, et al. Systematic discovery of Xist RNA binding proteins. *Cell*. 2015; 161(2):404–16. [PubMed: 25843628]
135. McHugh CA, et al. The Xist lncRNA interacts directly with SHARP to silence transcription through HDAC3. *Nature*. 2015; 521(7551):232–6. [PubMed: 25915022]
136. Moore MJ, et al. Mapping Argonaute and conventional RNA-binding protein interactions with RNA at single-nucleotide resolution using HITS-CLIP and CIMS analysis. *Nat Protoc*. 2014; 9(2):263–93. [PubMed: 24407355]

Highlights

Trends Box

- Somatic mutations or disease-associated SNPs of lncRNAs implicate lncRNAs as cancer risk genes
- Through RNA-protein, RNA-RNA, RNA-lipid interactions, lncRNAs modulate cancer signaling pathways and consequences
- Dysregulation of lncRNAs lead to hyper- or hypo-activation of cellular pathways, leading to resistance to current targeted therapies
- Targeting lncRNA alone or a co-targeting strategy may help overcome the targeted therapy resistance




Figure 1. The value of lncRNAs as breast cancer risk genes, diagnostic markers, prognostic markers and therapeutic targets

lncRNAs as cancer risk genes: the search for genomic mutations related to lncRNAs suggests that disease-related SNP of lncRNAs may situate lncRNAs as cancer risk genes. Populations with the wild type allele may exhibit low incidence of cancer; mutant allele carriers may show elevated incidence of cancer development.

lncRNAs as diagnostic markers: the detection of lncRNAs in human blood, urine or biopsy samples could be beneficial for risk detection in a gene carrier for early diagnosis of human cancer.

lncRNAs as prognostic markers: the expression status of lncRNAs in human cancer tissues could be correlated with cancer stage, metastatic potential, resistance to target therapy and patient outcome. The expression level of lncRNA could stratify cancer patients with target therapy.

lncRNAs as therapeutic targets: anti-sense oligonucleotides-based strategies are under development. siRNAs targeting lncRNAs could be encapsulated in nanoparticles for improved tissue distribution and pharmacodynamics. LNAs could also be the cargo of nanoparticles. Without delivery vehicles, LNAs exhibits adequate half-life in serum and tolerable toxicology.




Figure 2. LncRNAs are key regulators of cancer signaling

In response to extra- or intra-cellular signals, complicated signaling cascades are strictly regulated to achieve coordinate cellular activities. LncRNAs could be involved in all of the steps of signaling cascades: lncRNAs may associate with cellular receptors to modulate the hetero- and homo-dimers of the receptors; lncRNAs mediates the recruitment of kinases to receptors for activation/inactivation; lncRNAs intercedes second messenger-mediated signaling events; lncRNAs interacts with protein kinases to modulate the kinase-dependent post-translational modifications of effectors; lncRNAs facilitate the subcellular relocations of kinases/ effectors, lncRNAs regulate epigenetics modifications and assemble/dissemble of transcriptional machinery.




Figure 3. lncRNAs direct the outcome of a signaling network

The functional role of lncRNAs in regulating cancer signaling can be classified as following. Merge – The lncRNA conjoins the kinases of neighboring pathways, allowing the pathways to work in parallel to mediate a common cellular effect. Thus, the ligand of either receptor is able to activate the effector, accelerating the consequent cellular response. Switch – The lncRNA couples one receptor to multiple kinases, creating a junction in the pathway. When the appropriate ligand binds to the receptor, the linked kinases are each able to activate their respective effectors in response to that one signal protein. Reroute – In response to the cellular environment and specific ligand, the lncRNA will form a bridge between the kinase and one of many possible effectors. In this scenario, one receptor and its associated kinase are able to achieve an array of cellular effects in accordance to the cellular context. Yield – In the situation of antagonistic pathways, the lncRNA is able to mediate interaction between two kinases so that only one pathway is activated at a given time. Effectively, activation of a pathway is blocked when the other is already activated. Shortcut – In the presence of the lncRNA, the conventional kinase cascade is bypassed in favor of a shortcut that enables a more direct route to activating the downstream effector. Consequently, the lncRNA allows for more rapid induction of the desired cellular response. Detour – In instances where the conventional pathway is disrupted or blocked, lncRNAs can facilitate the formation of an alternative pathway by way of recruiting substitute pathway components or mediators. In

response to poisons or inhibitors, a cellular effect may still be achieved by the more circuitous route enabled by the lncRNA.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 4. The protein domains and RNA motifs involved in lnc-RNA-protein interactions

In addition to typical RNA binding domains (RBD), atypical RBDs and domain with unknown RNA binding mediate the interactions between lncRNAs and the key mediators of cancer signaling pathways. Non-canonical RNA-binding domains, such as the WD40 and SAM domains, are required for the RNA-protein complex formation upon ligand binding. Domains with unknown RNA-binding properties, including the DUF and SH3 domains, facilitate the recruitment of SNIP1 to lncRNA BCAR4 and LINK-A-BRK interaction. The RNA binding domains may recognize nucleotide sequences or structures of RNA motifs, resulting in specific lncRNA-protein interactions. The single-stranded lncRNA molecule forms complex secondary and 3-dimensional structures. Stem, base-pairing formed between two complementary strands of the RNA molecule. The double helices are essential for RNA folding, and also provide docking sites for sequence-mediated interaction. Stem-loop, the RNA sequence forms a complementary base-pairing with an unpaired loop. The nitrogenous bases within the single-stranded loop could face inside or outside of the loop to form additional hydrogen bonds with binding partners. Double stem-loop: two or more stem-loop structures side by side. The nitrogenous bases from both loops may coordinate the lncRNA-protein interaction. Bulge: the unpaired residues flanking with base-pairs may be packed toward the helix or extrude to outside of the stem, which are all important for protein binding. Symmetric and asymmetric interior loops: the structure of separate RNA strands flanked with stacking base-pairs can be found in the middle of RNA strands. The loops provide free nitrogenous bases for stacking interaction or hydrophobic interactions.




Figure 5. LncRNA governs the enzymatic activities of protein kinases in signaling circuitry
 Upon lncRNA-kinase interaction, the enzymatic activities of protein kinase could be modulated. Chaperones – The lncRNA interaction with subunits of an enzyme can induce a conformational change, altering its enzymatic activity. A–D illustrate the domains of the protein kinases, by which the inhibitory effect of domain D is repressed upon lncRNA binding, leading to enzymatic activation of domain A. Allosteric Regulators – When the lncRNA binds to the allosteric site of the enzyme, modifying the conformation of the regulatory domain (R) and kinase domain (K), the enzyme could be either inhibited or activated. Synergizers – The lncRNA conjoins multiple kinases and/or regulators together, mediating cooperative action on its effectors or substrates. Left panel illustrate that two kinases are orchestrated by lncRNA phosphorylation of effector. Right panel illustrate the scenario that the regulatory unit (R) and kinase (K) are bridged by lncRNAs as a mega complex for substrate modification. Camouflage – The presence of the lncRNA disguises the surface of target proteins, preventing the reorganization and post-translational modification

of target proteins by upstream signaling events. Transporter – the presence of the lncRNA facilitates the relocation of binding proteins from cytosol to mitochondria or shuttling between cytosol, nucleus and other subcellular compartments.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript